These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12706648)

  • 1. Surprising discovery with Alzheimer's medication.
    Thacker PD
    Drug Discov Today; 2003 May; 8(9):379-80. PubMed ID: 12706648
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
    Mustazza C; Borioni A; Del Giudice MR; Gatta F; Ferretti R; Meneguz A; Volpe MT; Lorenzini P
    Eur J Med Chem; 2002 Feb; 37(2):91-109. PubMed ID: 11858843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
    Stahl SM
    J Clin Psychiatry; 2000 Nov; 61(11):813-4. PubMed ID: 11105732
    [No Abstract]   [Full Text] [Related]  

  • 4. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
    Bentham P; Gray R; Sellwood E; Raftery J
    BMJ; 1999 Sep; 319(7210):640-1. PubMed ID: 10473490
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivastigmine in the treatment of Alzheimer's disease.
    Deleu D
    Eur Neurol; 2001; 46(2):110. PubMed ID: 11528167
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA approves new cholinesterase inhibitor for Alzheimer's disease.
    Am J Health Syst Pharm; 2000 Jun; 57(11):1026, 1028. PubMed ID: 10876742
    [No Abstract]   [Full Text] [Related]  

  • 8. [New perspectives for Alzheimer patients: acetylcholine inhibition with Rivastigmine. Congress of the European Neurologic Society. Nice, 6 July 199].
    Dtsch Med Wochenschr; 1998 Nov; 123(48 Suppl):1-4. PubMed ID: 9861229
    [No Abstract]   [Full Text] [Related]  

  • 9. Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
    Casademont J; Miró O; Rodriguez-Santiago B; Viedma P; Blesa R; Cardellach F
    J Neurol Sci; 2003 Jan; 206(1):23-6. PubMed ID: 12480080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ
    Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
    McMillan H
    Int J Geriatr Psychiatry; 1999 Dec; 14(12):1078-9. PubMed ID: 10607978
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
    Alagiakrishnan K; Sclater A; Robertson D
    J Am Geriatr Soc; 2003 Sep; 51(9):1326. PubMed ID: 12919253
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine: a review.
    Sim A
    Hosp Med; 1999 Oct; 60(10):731-5. PubMed ID: 10656066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
    Selai CE; Trimble MR; Rossor MN; Harvey RJ
    BMJ; 1999 Sep; 319(7210):641-2. PubMed ID: 10523095
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of rivastigmine in Alzheimer's disease. Guidelines do not ignore clinically relevant end points.
    Storosum JG; van Zwieten-Boot BJ; Elferink AJ
    BMJ; 1999 Sep; 319(7210):642. PubMed ID: 10523096
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
    Lojkowska W; Ryglewicz D; Jedrzejczak T; Minc S; Jakubowska T; Jarosz H; Bochynska A
    J Neurol Sci; 2003 Dec; 216(1):119-26. PubMed ID: 14607313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease: translating neurochemical insights into clinical benefits.
    J Clin Psychiatry; 2000 Oct; 61(10):791-802. PubMed ID: 11078045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.